Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20102
Title: Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.
Authors: Sud, S;O'Callaghan, C;Jonker, C;Karapetis, C;Price, T;Tebbutt, Niall C;Shapiro, J;Van Hazel, G;Pavlakis, N;Gibbs, P;Jeffrey, M;Siu, L;Gill, S;Wong, R;Jonker, D;Tu, D;Goodwin, R
Affiliation: Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON
Royal Melbourne Hospital, Melbourne, VIC, Australia
ncic Clinical Trials Group, Queen's University, Kingston, ON
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON
Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA
The Queen Elizabeth and University of Adelaide, Adelaide, SA
Austin Health, Heidelberg, Victoria, Australia
Department of Medical Oncology, Monash University, Melbourne, VIC
University of Western Australia, Perth, WA
Royal North Shore Hospital, Northern Clinical School, University of Sydney, St. Leonards, NSW
Oncology Service, Christchurch Hospital, Christchurch, N.Z
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON
University of British Columbia, BC Cancer, Vancouver, BC
CancerCare Manitoba, Winnipeg, MB
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON
ncic Clinical Trials Group, Queen's University, Kingston, ON
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON
Issue Date: Dec-2018
EDate: 2018-12
Citation: Current oncology (Toronto, Ont.) 2018; 25(6): e516-e526
Abstract: Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Using data from the Canadian Cancer Trials Group co.17 study [cetuximab vs. best supportive care (bsc)], we coded baseline htn and use of anti-htn medications, including bbs, for 572 patients. The chi-square test was used to assess the associations between those variables and baseline characteristics. Cox regression models were used for univariate and multivariate analyses of os and pfs by htn diagnosis and bb use. Baseline htn, bb use, and anti-htn medication use were not found to be prognostic for improved os. Baseline htn and bb use were not significant predictors of cetuximab benefit. In chemorefractory mcrc, neither baseline htn nor bb use is a significant prognostic factor. Baseline htn and bb use are not predictive of cetuximab benefit. Further investigation to determine whether baseline htn or bb use have a similarly insignificant impact on prognosis in patients receiving earlier lines of treatment remains warranted.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20102
DOI: 10.3747/co.25.4069
PubMed URL: 30607118
Type: Journal Article
Subjects: Colorectal cancer
hypertension
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.